Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Aardvark Therapeutics faces a securities class action alleging ARD-101 was less safe than investors were led to believe, with clinical/regulatory/commercial prospects overstated. The complaint points to Aardvark’s Feb. 27, 2026 decision to voluntarily pause its Phase 3 HERO trial after safety observations in a healthy volunteer study. Following that disclosure, the stock fell $7.02 per share (56.2%) to close at $5.47 on Mar. 2, 2026, and the lead-plaintiff deadline is set for Oct. 13, 2026.

Analysis

This is more than a legal headline: it hardens the market’s view that the asset is not just delayed, but potentially non-viable at commercially useful doses. For a pre-revenue biotech, that shifts the valuation anchor from peak-sales optionality to liquidation/recovery value, which tends to compress EV long before the court case resolves. The practical overhang is financing — any rerun of the program now comes with higher cash burn, weaker negotiating leverage with partners, and a materially worse cost of capital.

The second-order effect is on the biotech IPO window and on similarly structured small-cap names that have leaned on “clean safety” narratives to justify premium pricing. Even if the lawsuit is backward-looking, investors will demand more evidence around cardiac monitoring, dose-response, and tolerability before underwriting any new obesity/appetite or GI-linked story. That can hit upcoming offerings and secondary issuance terms across the group, especially where catalysts are >6 months out and cash runway is tight.

Contrarian view: the move is likely largely in the stock already, so the lawsuit itself is not the fresh catalyst. What still matters is whether management can credibly restart dosing, whether the FDA imposes any broader hold, and whether the company has enough balance-sheet runway to survive another multi-quarter delay. If no clean re-dosing update lands in the next 1-3 months, the stock remains a time-decay short; if it does, the right-size damage may be less about trial termination and more about a much smaller future market than bulls assumed.

Key Decisions for Investors

• Do not chase AARD long on any sympathy bounce; for holders, use rallies to reduce exposure into strength over the next 1-3 sessions. Risk/reward is poor because the upside requires a clean clinical reset, while downside is driven by financing dilution and incremental safety scrutiny.
• If borrow and liquidity allow, keep AARD on a tactical short list for 1-3 months and add on failed bounce attempts rather than into downside gaps. Falsifier: a company update showing FDA-cleared restart and no meaningful cardiac signal.
• Watch XBI as the cleaner way to express broader biotech risk appetite; avoid assuming this case is sector-wide unless other small-cap trial-safety headlines stack up. AARD-specific litigation is a poor reason to short the whole basket absent confirmation from peers.
• Set an alert for any new AARD disclosure on cash runway, protocol amendments, or partner outreach. If the company needs external capital before a restart, the equity is likely to re-rate lower again even without fresh negative trial data.